

1. Scher HI, Heller G. Clinical states in prostate cancer: towards a dynamic model of disease progression. *Urology* 2000;55:323–327.
2. American Cancer Society. Cancer facts and figures 2014. <http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/>. Accessed May 29, 2014.
3. SEER Program. SEER stat fact sheets: prostate cancer. <http://seer.cancer.gov/statfacts/html/prost.html>. Accessed May 29, 2014.
4. Prostate.net. Prostate cancer statistics. <http://www.prostate.net/prostate-cancer/prostate-cancer-statistics/>. Accessed May 29, 2014.
5. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. *Eur Urol* 2012;61:1079–1092.
6. Sakr WA, Grignon DJ, Crissman JD, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20–69: an autopsy study of 249 cases. *In Vivo* 1994;8:439–443.
7. Haenszel W, Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. *J Natl Cancer Inst* 1968;40:43–68.
8. Scardino PT, Weaver R, Hudson MA. Early detection of prostate cancer. *Hum Pathol* 1992;23:211–222.
9. Kosary CL, Ries LAG, Miller BA, et al. *SEER cancer incidence public-use database, 1970–1980*. Bethesda, MD: National Cancer Institute; 1998.
10. Smith JR, Freije D, Carpten JD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome wide search. *Science* 1996;274:1371–1374.
11. Wilson KM, Giovannucci EL, Mucci LA. Lifestyle and dietary factors in the prevention of lethal prostate cancer. *Asian J Androl* 2012;14:365–374.
12. Scardino PT. Prostate cancer: improving PSA testing by adjusting for genetic background. *Nat Rev Urol* 2013;10:190–192.
13. Ewing CM, Ray AM, Lange EM, et al. Germline mutation in HOXB13 and prostate-cancer risk. *N Engl J Med* 2012;366:141–149.
14. Gallagher DJ, Gaudet MM, Pal P, et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. *Clin Cancer Res* 2010;16:2115–2121.
15. Demark-Wahnefried W, Strigo T, Catoe K, et al. Knowledge, beliefs, and prior screening behavior among blacks and whites reporting for prostate cancer screening. *Urology* 1995;46:346–351.
16. Polednak AP, Flannery JT. Black versus white racial differences in clinical stage at diagnosis and treatment of prostatic cancer in Connecticut. *Cancer* 1992;70:2152–2158.
17. Vertosick EA, Poon BY, Vickers AJ. Relative value of race, family history and prostate-specific antigen as indications for early initiation of prostate cancer screening. *J Urol* 2014 [Epub ahead of print]. doi: 10.1016/j.juro.2014.03.032
18. Cook LS, Goldoft M, Schwartz SM, et al. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. *J Urol* 1999;161:152–155.
19. Bosland MC, Oakley-Girvan I, Whittemore AS. Dietary fat, calories, and prostate cancer risk. *J Natl Cancer Inst* 1999;91:489–491.
20. Correa P. Epidemiological correlations between diet and cancer frequency. *Cancer Res* 1981;41:3685–3690.
21. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. *Eur Urol* 2013;63:800–809.
22. Muller RL, Gerber L, Moreira DM, et al. Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride. *Eur Urol* 2013;63:1115–1121.
23. Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. *Cancer Prev Res (Phila)* 2011;4:486–501.
24. Ma J, Li H, Giovannucci E, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. *Lancet Oncol* 2008;9:1039–1047.
25. Kenfield SA, Stampfer MJ, Giovannucci E, et al. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. *J Clin Oncol* 2011;29:726–732.
26. Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *JAMA* 2011;306:1549–1556.
27. Peters U, Littman AJ, Kristal AR, et al. Vitamin E and selenium supplementation and risk of prostate cancer in the Vitamins and lifestyle (VITAL) study cohort. *Cancer Causes Control* 2008;19:75–87.
28. Giovannucci E, Ascherio A, Rimm EB, et al. Intake of carotenoids and retinol in relation to risk of prostate cancer. *J Natl Cancer Inst* 1995;87:1767–1776.
29. Giovannucci E, Rimm EB, Liu Y, et al. A prospective study of tomato products, lycopene, and prostate cancer risk. *J Natl Cancer Inst* 2002;94:391–398.
30. Demark-Wahnefried W, Halabi S, Paulson DF. Serum androgens: associations with prostate cancer risk and hair patterning. *J Androl* 1998;19:631.
31. Papatroka T, Delviks-Frankenberry KA, Cingoz O, et al. Recombinant origin of the retrovirus XMRV. *Science* 2011;333:97–101.
32. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. *N Engl J Med* 2003;349:215–224.
33. Scardino PT. The prevention of prostate cancer—the dilemma continues. *N Engl J Med* 2003;349:297–299.
34. Theoret MR, Ning YM, Zhang JJ, et al. The risks and benefits of 5 α -reductase inhibitors for prostate-cancer prevention. *N Engl J Med* 2011;365:97–99.
35. Thompson IM Jr, Goodman PJ, Tangen CM, et al. Long-term survival of participants in the prostate cancer prevention trial. *N Engl J Med* 2013;369:603–610.
36. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. *N Engl J Med* 2010;362:1192–1202.
37. US Food and Drug Administration. FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer. June 9, 2011. Accessed May 21, 2014. <http://www.fda.gov/Drugs/DrugSafety/ucm258314.htm>.
38. Schmitz-Drager BJ, Schoffski O, Marberger M, et al. Risk adapted chemoprevention for prostate cancer: an option? *Recent Results Cancer Res* 2014;202:79–91.
39. Ohori M, Scardino PT. Localized prostate cancer. *Curr Probl Surg* 2002;39:833–957.
40. Epstein JI, Algaba F, Allsbrook WC Jr, et al. Tumors of the prostate. In Eble NJ, Sauter G, Epstein JI, et al., eds. *World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs*. Lyon, France: IARC Press; 2004:159–216.
41. DeMarzo AM, Nelson WG, Isaacs WB, et al. Pathological and molecular aspects of prostate cancer. *Lancet* 2003;361:955–964.
42. Nelson WG, DeMarzo AM, Isaacs WB. Prostate cancer. *N Engl J Med* 2003;349:366–381.
43. Montie JE, Pienta KJ. Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. *Urology* 1994;43:892–899.
44. De Marzo AM, Marchi VL, Epstein JI, et al. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. *Am J Pathol* 1999;155:1985–1992.
45. Bostwick DG. Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. *Cancer* 1996;78:330–336.
46. Bostwick DG, Brawer MK. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. *Cancer* 1987;59:788–794.
47. Sakr WA. Prostatic intraepithelial neoplasia: a marker for high-risk groups and a potential target for chemoprevention. *Eur Urol* 1999;35:474–478.
48. De Marzo AM, Platz EA, Epstein JI, et al. A working group classification of focal prostate atrophy lesions. *Am J Surg Pathol* 2006;30:1281–1291.
49. Schlessinger C, Bostwick DG, Iczkowski KA. High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: predictive value for cancer in current practice. *Am J Surg Pathol* 2005;29:1201–1207.
50. Beahrs OH, Henson DE, Hutter RVP, et al. *American Joint Committee on Cancer. AJCC Cancer Staging Manual*. 4th ed. Philadelphia, PA: Lippincott-Raven, 1992.
51. Edge S, Byrd DR, Compton CC, et al. *American Joint Committee on Cancer. AJCC Cancer Staging Manual*. 7th ed. New York: Springer, 2010.
52. Fleming ID, Cooper JS, Henson DE, et al. *American Joint Committee on Cancer. AJCC Cancer Staging Manual*. 5th ed. Philadelphia: JB Lippincott, 1997.
53. Gleason DF. Classification of prostatic carcinomas. *Cancer Chemother Rep* 1966;50:125–128.
54. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. *J Urol* 1974;111:58–64.
55. Epstein JI. Prognostic significance of tumor volume in radical prostatectomy and needle biopsy specimens. *J Urol* 2011;186:790–797.
56. Epstein JI, Allsbrook WC Jr, Amin MB, et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma. *Am J Surg Pathol* 2005;29:1228–1242.
57. Aihara M, Wheeler TM, Ohori M, et al. Heterogeneity of prostate cancer in radical prostatectomy specimens. *Urology* 1994;43:60–66.
58. Noguchi M, Stamey TA, Neal JE, et al. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. *J Urol* 2000;163:1751–1755.
59. Morgan TM, Welty CJ, Vakar-Lopez F, et al. Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen. *J Urol* 2010;184:2303–2307.
60. Nadal R, Schweizer M, Kryvenko ON, et al. Small cell carcinoma of the prostate. *Nat Rev Urol* 2014;11:213–219.
61. Ginesin Y, Bolker M, Moskovitz B, et al. Carcinosarcoma of the prostate. *Eur Urol* 1986;12:441–442.
62. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,650 men. *J Urol* 1994;151:1283–1290.
63. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. *CA Cancer J Clin* 2014;64:9–29.

64. Lilja H, Piironen TP, Rittenhouse HG, et al. Value of molecular forms of prostate-specific antigen and related kallikreins, hK2, in diagnosis and staging of prostate cancer. In Vogelzang NA, Scardino PT, Shipley WU, et al. *Comprehensive Textbook of Genitourinary Oncology*. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2000:638–650.
65. Aihara M, Lebovitz RM, Wheeler TM, et al. Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer. *J Urol* 1994;151:1558–1564.
66. Eastham JA, Riedel E, Scardino PT, et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. *JAMA* 2003;289:2695–2700.
67. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. *N Engl J Med* 2004;350:2239–2246.
68. Lilja H, Cronin AM, Dahlin A, et al. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. *Cancer* 2011;117:1210–1219.
69. Orsted DD, Bojesen SE, Kamstrup PR, et al. Long-term prostate-specific antigen velocity in improved classification of prostate cancer risk and mortality. *Eur Urol* 2013;64:384–393.
70. Vickers AJ, Cronin AM, Bjork T, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. *BMJ* 2010;341:e4521.
71. Orsted DD, Nordestgaard BG, Jensen GB, et al. Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population. *Eur Urol* 2012;61:865–874.
72. MSKCC Prostate Cancer: Screening Guidelines. Accessed May 6, 2014. <http://www.mskcc.org/cancer-care/adult/prostate/screening-guidelines-prostate>.
73. Ulmert D, Cronin AM, Bjork T, et al. Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. *BMC Med* 2008;6:6.
74. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. *Lancet Oncol* 2010;11:725–732.
75. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. *Cochrane Database Syst Rev* 2009:CD001877.
76. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. *Lancet* 2012;380:1778–1786.
77. Paci E, Euroscreen Working Group. Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. *J Med Screen* 2012;19:5–13.
78. Elmunzer BJ, Hayward RA, Schoenfeld PS, et al. Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. *PLoS Med* 2012;9:e1001352.
79. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. *N Engl J Med* 2009;360:1320–1328.
80. Cooperberg MR, Cowan JE, Hilton JF, et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer. *J Clin Oncol* 2011;29:228–234.
81. Hugosson J, Aus G, Lilja H, et al. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. *Cancer* 2004;100:1397–1405.
82. Bellardita L, Rancati T, Alvisi MF, et al. Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance. *Eur Urol* 2013;64:30–36.
83. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. *J Clin Oncol* 2010;28:1117–1123.
84. Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. *J Clin Oncol* 2010;28:126–131.
85. Taneja SS. Re: active surveillance for low-risk prostate cancer worldwide: the PRIAS study. *J Urol* 2013;189:1322.
86. Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. *J Clin Oncol* 2011;29:2185–2190.
87. Moyer VA. U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2012;157:120–134.
88. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. *N Engl J Med* 2009;360:1310–1319.
89. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. *J Natl Cancer Inst* 2012;104:125–132.
90. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. *N Engl J Med* 2012;366:981–990.
91. Chou R, Crosswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med* 2011;155:762–771.
92. Carlsson S, Vickers AJ, Roobol M, et al. Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. *J Clin Oncol* 2012;30:2581–2584.
93. Vickers AJ, Roobol MJ, Lilja H. Screening for prostate cancer: early detection or overdiagnosis? *Annu Rev Med* 2012;63:161–170.
94. Heijnsdijk EA, Wever EM, Auvinen A, et al. Quality-of-life effects of prostate-specific antigen screening. *N Engl J Med* 2012;367:595–605.
95. Basch E, Oliver TK, Vickers A, et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. *J Clin Oncol* 2012;30:3020–3025.
96. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA Guideline. *J Urol* 2013;190:419–426.
97. American Cancer Society. Can prostate cancer be found early? Updated March 12, 2014. Accessed June 6, 2014. <http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-detection>.
98. Stamey TA, Sozen S, Yemoto CM, et al. Classification of localized untreated prostate cancer based on 791 men treated only with radical prostatectomy: common ground for therapeutic trials and TNM subgroups. *J Urol* 1998;159:2009–2012.
99. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. *J Natl Cancer Inst* 1998;90:766–771.
100. Pound CR, Partin AW, Epstein JI, et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. *Cancer* 1997;79:528–537.
101. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. *JAMA* 1993;270:860–864.
102. Pettaway J, Brawer MK. Age specific versus 4.0 ng/ml as a PSA cutoff in the screening population: impact on cancer detection (abstract). *J Urol* 1995;153:465A.
103. Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. *J Urol* 1992;147:815–816.
104. Stamey T, Yang N, Hay A, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. *N Engl J Med* 1987;317:909–916.
105. Ohori M, Scardino PT. Early detection of prostate cancer: the nature of cancers detected with current diagnostic tests. *Semin Oncol* 1994;21:522–526.
106. Carter HB, Epstein JI, Chan DW, et al. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. *JAMA* 1997;277:1456–1460.
107. O'Brien MF, Cronin AM, Fearn PA, et al. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. *J Clin Oncol* 2009;27:3591–3597.
108. Loeb S, Sokoll LJ, Broyles DL, et al. Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration. *J Urol* 2013;189:1702–1706.
109. Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. *J Urol* 2011;185:1650–1655.
110. Christensson A, Bruun L, Bjork T, et al. Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer. *BJU Int* 2011;107:1769–1774.
111. Vickers AJ, Gupta A, Savage CJ, et al. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. *Cancer Epidemiol Biomarkers Prev* 2011;20:255–261.
112. Heidenreich A, Abrahamsson PA, Artibani W, et al. Early detection of prostate cancer: European Association of Urology recommendation. *Eur Urol* 2013;64:347–354.
113. Dijkstra S, Mulders PF, Schalken JA. Clinical use of novel urine and blood based prostate cancer biomarkers: a review. *Clin Biochem* 2014;47:889–896.
114. Catalona W, Richie J, deKernion JB, et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer. *J Urol* 1994;152:2031–2036.
115. Epstein JI, Pound CR, Partin AW, et al. Disease progression following radical prostatectomy in men with Gleason score 7 tumor. *J Urol* 1998;160:97–100.
116. Gleason DF. Histologic grade, clinical stage, and patient age in prostate cancer. *NCI Monogr* 1988:15–18.
117. Porten SP, Whitson JM, Cowan JE, et al. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. *J Clin Oncol* 2011;29:2795–2800.
118. Whitson JM, Porten SP, Hilton JF, et al. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. *J Urol* 2011;185:1656–1660.
119. D'Amico AV, Whittington R, Malkowicz SB, et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. *J Clin Oncol* 2000;18:1164–1172.
120. Epstein JI, Walsh PC, Carmichael M, et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. *JAMA* 1994;271:368–374.
121. Goto Y, Ohori M, Arakawa A, et al. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. *J Urol* 1996;156:1059–1063.

122. Ohori M, Suyama K, Maru N, et al. Prognostic significance of systemic needle biopsy findings. *J Urol* 2000;163:287A.
123. Barqawi AB, Rove KO, Gholizadeh S, et al. The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer. *J Urol* 2011;186:80–85.
124. Rastinehad AR, Baccala AA Jr, Chung PH, et al. D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging. *J Urol* 2011;185:815–820.
125. Mohler JL, Kantoff PW, Armstrong AJ, et al. NCCN Guidelines: Prostate cancer, version 2.2014. *J Natl Compr Canc Netw* 2014;12:686–718.
126. Vargas HA, Akin O, Shukla-Dave A, et al. Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study. *Radiology* 2012;265:478–487.
127. Yoshimitsu K, Kiyoshima K, Irie H, et al. Usefulness of apparent diffusion coefficient map in diagnosing prostate carcinoma: correlation with stepwise histopathology. *J Magn Reson Imaging* 2008;27:132–139.
128. Futterer JJ, Engelbrecht MR, Huisman HJ, et al. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. *Radiology* 2005;237:541–549.
129. Villers A, Puech P, Mouton D, et al. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. *J Urol* 2006;176:2432–2437.
130. Hricak H, Choyke PL, Eberhardt SC, et al. Imaging prostate cancer: a multidisciplinary perspective. *Radiology* 2007;243:28–53.
131. Lin K, Szabo Z, Chin BB, et al. The value of a baseline bone scan in patients with newly diagnosed prostate cancer. *Clin Nucl Med* 1999;24:579–582.
132. Sciarra A, Barentsz J, Bjartell A, et al. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. *Eur Urol* 2011;59:962–977.
133. Greene FL, Page DL, Fleming ID, et al. *American Joint Committee on Cancer. AJCC Cancer Staging Manual*. 6th ed. New York: Springer, 2002.
134. Ohori M, Wheeler TM, Scardino PT. The New American Joint Committee on Cancer and International Union against Cancer TNM classification of prostate cancer. *Cancer* 1994;74:104–114.
135. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. *Urology* 2001;58:843–848.
136. Eifler JB, Feng Z, Lin BM, et al. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. *BJU Int* 2013;111:22–29.
137. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. *JAMA* 1998;280:969–974.
138. Mitchell JA, Cooperberg MR, Elkin EP, et al. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. *J Urol* 2005;173:1126–1131.
139. Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. *J Clin Oncol* 2009;27:4300–4305.
140. Kattan MW, Zelefsky MJ, Kupelian PA, et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. *J Clin Oncol* 2000;18:3352–3359.
141. Kattan MW, Potters L, Blasko JC, et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. *Urology* 2001;58:393–399.
142. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *N Engl J Med* 2004;351:2817–2826.
143. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. *J Clin Oncol* 2006;24:3726–3734.
144. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. *Lancet Oncol* 2010;11:55–65.
145. Holt S, Bertelli G, Humphreys I, et al. A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pN1mi, ER-positive breast cancer in the U.K. *Br J Cancer* 2013;108:2250–2258.
146. Cuzick J, Bamey DM, Fisher G, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. *Br J Cancer* 2012;106:1095–1099.
147. Shore N, Concepcion R, Saltzstein D, et al. Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer. *Curr Med Res Opin* 2014;30:547–553.
148. Bishoff JT, Freedland SJ, Gerber L, et al. Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. *J Urol* 2014;192:409–414.
149. Klein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. *Eur Urol* 2014 [Epub ahead of print]. doi: 10.1016/j.eururo.2014.05.004.
150. Cuzick JM, Stone S, Fisher G, et al. Validation of an RNA cell cycle progression (CCP) score for predicting prostate cancer death in a conservatively managed needle biopsy cohort. *J Clin Oncol* 2014;32:Abstr 5059.
151. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. *J Clin Oncol* 2005;23:7005–7012.
152. Stephenson AJ, Scardino PT, Bianco FJ Jr, et al. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. *J Urol* 2004;172:2239–2243.
153. Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. *J Natl Cancer Inst* 2006;98:715–717.
154. Eggener SE, Scardino PT, Walsh PC, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. *J Urol* 2011;185:869–875.
155. Food and Drug Administration. *Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics*. May 2007. Accessed May 21, 2014. <http://www.fda.gov/downloads/Drugs/.../Guidances/ucm071590.pdf>.
156. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009;45:228–247.
157. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. *J Clin Oncol* 2008;26:1148–1159.
158. Smith MR. Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer. *J Urol* 2003;170:S55–S57.
159. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. *J Natl Cancer Inst* 2002;94:1458–1468.
160. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. *N Engl J Med* 2012;367:203–213.
161. Berglund A, Garmo H, Tishelman C, et al. Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. *J Urol* 2011;185:833–839.
162. Vargas HA, Akin O, Afaq A, et al. Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer. *J Urol* 2012;188:1732–1738.
163. Liu D, Lehmann HP, Frick KD, et al. Active surveillance versus surgery for low risk prostate cancer: a clinical decision analysis. *J Urol* 2012;187:1241–1246.
164. Mullins JK, Bonekamp D, Landis P, et al. Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance. *BJU Int* 2013;111:1037–1045.
165. Walsh PC. Anatomic radical prostatectomy: evolution of the surgical technique. *J Urol* 1998;160:2418–2424.
166. Godoy G, von Bodman C, Chade DC, et al. Pelvic lymph node dissection for prostate cancer: frequency and distribution of nodal metastases in a contemporary radical prostatectomy series. *J Urol* 2012;187:2082–2086.
167. Burkhard FC, Bader P, Schneider E, et al. Reliability of preoperative values to determine the need for lymphadenectomy in patients with prostate cancer and meticulous lymph node dissection. *Eur Urol* 2002;42:84–90.
168. Schumacher MC, Burkhard FC, Thalmann GN, et al. Is pelvic lymph node dissection necessary in patients with a serum PSA < 10 ng/ml undergoing radical prostatectomy for prostate cancer? *Eur Urol* 2006;50:272–279.
169. Feifer AH, Elkin EB, Lowrance WT, et al. Temporal trends and predictors of pelvic lymph node dissection in open or minimally invasive radical prostatectomy. *Cancer* 2011;117:3933–3942.
170. Allaf ME, Palapattu GS, Trock BJ, et al. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. *J Urol* 2004;172:1840–1844.
171. Bader P, Burkhard FC, Markwalder R, et al. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? *J Urol* 2002;168:514–518, discussion 518.
172. Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. *J Urol* 2002;167:1681–1686.
173. Touijer K, Rabbani F, Otero JR, et al. Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%. *J Urol* 2007;178:120–124.
174. Cagiannos I, Karakiewicz P, Eastham JA, et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. *J Urol* 2003;170:1798–1803.
175. Touijer KA, Ahallal Y, Guillonneau BD. Indications for and anatomical extent of pelvic lymph node dissection for prostate cancer: practice patterns of uro-oncologists in North America. *Urol Oncol* 2013;31:1517–1521.
176. Touijer KA, Mazzola CR, Sjoberg DD, et al. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. *Eur Urol* 2014;65:20–25.
177. Carlsson SV, Tafe LJ, Chade DC, et al. Pathological features of lymph node metastasis for predicting biochemical recurrence after radical prostatectomy for prostate cancer. *J Urol* 2013;189:1314–1318.
178. von Bodman C, Godoy G, Chade DC, et al. Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy. *J Urol* 2010;184:143–148.

179. Bianco FJ Jr, Scardino PT, Eastham JA. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). *Urology* 2005;66:83–94.
180. Vickers A, Savage C, Bianco F, et al. Cancer control and functional outcomes after radical prostatectomy as markers of surgical quality: analysis of heterogeneity between surgeons at a single cancer center. *Eur Urol* 2011;59:317–322.
181. Vickers AJ, Bianco FJ, Serio AM, et al. The surgical learning curve for prostate cancer control after radical prostatectomy. *J Natl Cancer Inst* 2007;99:1171–1177.
182. Gandaglia G, Sammon JD, Chang SL, et al. Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. *J Clin Oncol* 2014;32:1419–1426.
183. Eastham J, Scardino PT. Radical prostatectomy. In Campbell MF, Walsh PC, eds. *Campbell's Urology*. 7th ed. Philadelphia: W.B. Saunders; 1998:2547–2564.
184. Hu JC, Gu X, Lipsitz SR, et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. *JAMA* 2009;302:1557–1564.
185. Lowrance WT, Elkin EB, Jacks LM, et al. Comparative effectiveness of prostate cancer surgical treatments: a population based analysis of postoperative outcomes. *J Urol* 2010;183:1366–1372.
186. Lepor H. Open versus laparoscopic radical prostatectomy. *Rev Urol* 2005;7:115–127.
187. Murphy DG, Bjartell A, Ficarra V, et al. Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. *Eur Urol* 2010;57:735–746.
188. Bill-Axelsson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. *N Engl J Med* 2014;370:932–942.
189. Bill-Axelsson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. *N Engl J Med* 2005;352:1977–1984.
190. Vickers A, Bettecette C, Steineck G, et al. Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. *Eur Urol* 2012;62:204–209.
191. Lane JA, Hamdy FC, Martin RM, et al. Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. *Eur J Cancer* 2010;46:3095–3101.
192. Roehl KA, Han M, Ramos CG, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long term results. *J Urol* 2004;172:910–914.
193. Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. *J Urol* 2003;169:517–523.
194. Hull GW, Rabbani F, Abbas F, et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. *J Urol* 2002;167:528–534.
195. Trapasso JG, deKernion JB, Smith RB, et al. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. *J Urol* 1994;152:1821–1825.
196. Zincke H, Oesterling JE, Blute ML, et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. *J Urol* 1994;152:1850–1857.
197. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. *JAMA* 2009;302:1202–1209.
198. Han M, Partin AW, Pound CR, et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. *Urol Clin North Am* 2001;28:555–565.
199. Yossepowitch O, Eggenner SE, Bianco FJ Jr, et al. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. *J Urol* 2007;178:493–499.
200. Yossepowitch O, Eggenner SE, Serio AM, et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. *Eur Urol* 2008;53:950–959.
201. Chang AJ, Autio KA, Roach M 3rd, et al. High-risk prostate cancer-classification and therapy. *Nat Rev Clin Oncol* 2014;11:308–323.
202. Begg CB, Riedel ER, Bach PB, et al. Variations in morbidity after radical prostatectomy. *N Engl J Med* 2002;346:1138–1144.
203. Zelefsky MJ, Kollmeier M, Cox B, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. *Int J Radiat Oncol Biol Phys* 2012;84:125–129.
204. Beckendorf V, Guerif S, Le Prise E, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. *Int J Radiat Oncol Biol Phys* 2011;80:1056–1063.
205. Al-Mamgani A, van Putten WL, Heemsbergen WD, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. *Int J Radiat Oncol Biol Phys* 2008;72:980–988.
206. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. *Int J Radiat Oncol Biol Phys* 2008;70:67–74.
207. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. *J Clin Oncol* 2010;28:1106–1111.
208. Deamaley DP, Jovic G, Syndikus I, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. *Lancet Oncol* 2014;15:464–473.
209. Eade TN, Hanlon AL, Horwitz EM, et al. What dose of external-beam radiation is high enough for prostate cancer? *Int J Radiat Oncol Biol Phys* 2007;68:682–689.
210. Kupelian P, Kuban D, Thames H, et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. *Int J Radiat Oncol Biol Phys* 2005;61:415–419.
211. Lyons JA, Kupelian PA, Mohan DS, et al. Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. *Urology* 2000;55:85–90.
212. Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. *J Urol* 2001;166:876–881.
213. Kuban DA, Levy LB, Cheung MR, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? *Int J Radiat Oncol Biol Phys* 2011;79:1310–1317.
214. Spratt DE, Pei X, Yamada J, et al. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. *Int J Radiat Oncol Biol Phys* 2013;85:686–692.
215. Zelefsky MJ, Ginor RX, Fuks Z, et al. Efficacy of selective alpha-1 blocker therapy in the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer. *Int J Radiat Oncol Biol Phys* 1999;45:567–570.
216. Sebastian S, O'Connor H, O'Morain C, et al. Argon plasma coagulation as first-line treatment for chronic radiation proctopathy. *J Gastroenterol Hepatol* 2004;19:1169–1173.
217. Dall'Era MA, Hampson NB, Hsi RA, et al. Hyperbaric oxygen therapy for radiation induced proctopathy in men treated for prostate cancer. *J Urol* 2006;176:87–90.
218. Corman JM, McClure D, Pritchett R, et al. Treatment of radiation induced hemorrhagic cystitis with hyperbaric oxygen. *J Urol* 2003;169:2200–2202.
219. Zelefsky MJ, Pei X, Teslova T, et al. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention. *BJU Int* 2012;110:1696–1701.
220. Zelefsky MJ, Chan H, Hunt M, et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. *J Urol* 2006;176:1415–1419.
221. Ghadjar P, Zelefsky MJ, Spratt DE, et al. Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer. *Int J Radiat Oncol Biol Phys* 2014;88:339–344.
222. van der Wielen GJ, Mulhall JP, Incrocci L. Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: a critical review. *Radiation Oncol* 2007;84:107–113.
223. Higgins GS, McLaren DB, Kerr GR, et al. Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy. *Int J Radiat Oncol Biol Phys* 2006;65:982–989.
224. Kupelian PA, Thakkar VV, Khuntia D, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. *Int J Radiat Oncol Biol Phys* 2005;63:1463–1468.
225. Anwar M, Weinberg V, Chang AJ, et al. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir. *Radiat Oncol* 2014;9:42.
226. Katz AJ, Santoro M, Ashley R, et al. Stereotactic body radiotherapy for organ-confined prostate cancer. *BMC Urol* 2010;10:1.
227. King CR, Brooks JD, Gill H, et al. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. *Int J Radiat Oncol Biol Phys* 2012;82:877–882.
228. King CR, Freeman D, Kaplan I, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. *Radiation Oncol* 2013;109:217–221.
229. Mendenhall NP, Hoppe BS, Nichols RC, et al. Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. *Int J Radiat Oncol Biol Phys* 2014;88:596–602.
230. Hoppe BS, Michalski JM, Mendenhall NP, et al. Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. *Cancer* 2014;120:1076–1082.
231. Sheets NC, Goldin GH, Meyer AM, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. *JAMA* 2012;307:1611–1620.
232. Grimm PD, Blasko JC, Sylvester JE, et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125I) brachytherapy. *Int J Radiat Oncol Biol Phys* 2001;51:31–40.
233. Merrick GS, Butler WM, Wallner KE, et al. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer. *W Virginia Med J* 2005;101:168–171.
234. Morris WJ, Keyes M, Spadinger I, et al. Population-based 10-year oncologic outcomes after low-dose-rate brachytherapy for low-risk and intermediate-risk prostate cancer. *Cancer* 2013;119:1537–1546.

235. Potters L, Morgenstern C, Calugaru E, et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. *J Urol* 2005;173:1562–1566.
236. Zelefsky MJ, Chou JF, Pei X, et al. Predicting biochemical tumor control after brachytherapy for clinically localized prostate cancer: The Memorial Sloan-Kettering Cancer Center experience. *Brachytherapy* 2012;11:245–249.
237. Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. *Int J Radiat Oncol Biol Phys* 2007;67:327–333.
238. Nag S, Bice W, DeWyngaert K, et al. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. *Int J Radiat Oncol Biol Phys* 2000;46:221–230.
239. Stock RG, Stone NN, Cesaretti JA, et al. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. *Int J Radiat Oncol Biol Phys* 2006;64:527–533.
240. Guedea F, Aguiló F, Polo A, et al. Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1-T2 prostate cancer. *Radiother Oncol* 2006;80:57–61.
241. Khaksar SJ, Laing RW, Henderson A, et al. Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy. *BJU Int* 2006;98:1210–1215.
242. Zelefsky MJ, Yamada Y, Cohen GN, et al. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. *Int J Radiat Oncol Biol Phys* 2007;67:65–70.
243. Sylvester JE, Grimm PD, Blasko JC, et al. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. *Int J Radiat Oncol Biol Phys* 2007;67:57–64.
244. Keyes M, Miller S, Mirvan V, et al. Acute and late urinary toxicity in 606 prostate brachytherapy patients—The BC Cancer Agency experience. American Brachytherapy Society 2007 Annual Meeting. *Brachytherapy* 2007;6:91.
245. Kollmeier MA, Stock RG, Cesaretti J, et al. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy. *J Urol* 2005;173:808–812.
246. Peters CA, Cesaretti JA, Stone NN, et al. Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease. *Int J Radiat Oncol Biol Phys* 2006;66:424–429.
247. Merrick GS, Butler WM, Wallner KE, et al. Risk factors for the development of prostate brachytherapy related urethral strictures. *J Urol* 2006;175:1376–1380.
248. Waterman FM, Dicker AP. Probability of late rectal morbidity in 125I prostate brachytherapy. *Int J Radiat Oncol Biol Phys* 2003;55:342–353.
249. Gelblum DY, Potters L, Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. *Int J Radiat Oncol Biol Phys* 2000;48:119–124.
250. Gelblum DY, Potters L, Ashley R, et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. *Int J Radiat Oncol Biol Phys* 1999;45:59–67.
251. Bottomley D, Ash D, Al-Qaisieh B, et al. Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds. *Radiother Oncol* 2007;82:46–49.
252. Lee WR, Bae K, Lawton C, et al. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019. *Cancer* 2007;109:1506–1512.
253. Shah JN, Wu CS, Katz AE, et al. Improved biochemical control and clinical disease-free survival with intraoperative versus preoperative preplanning for transperineal interstitial permanent prostate brachytherapy. *Cancer J* 2006;12:289–297.
254. Keyes M, Schellenberg D, Moravan V, et al. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: the effect of learning curve? *Int J Radiat Oncol Biol Phys* 2006;64:825–834.
255. Albert M, Tempany CM, Schultz D, et al. Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy. *Cancer* 2003;98:949–954.
256. Snyder KM, Stock RG, Hong SM, et al. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. *Int J Radiat Oncol Biol Phys* 2001;50:335–341.
257. Zelefsky MJ, Yamada Y, Cohen GN, et al. Intraoperative real-time planned conformal prostate brachytherapy: post-implantation dosimetric outcome and clinical implications. *Radiother Oncol* 2007;84:185–189.
258. Merrick GS, Butler WM, Wallner KE, et al. Erectile function after prostate brachytherapy. *Int J Radiat Oncol Biol Phys* 2005;62:437–447.
259. Merrick GS, Butler WM, Lief JH, et al. Efficacy of sildenafil citrate in prostate brachytherapy patients with erectile dysfunction. *Urology* 1999;53:1112–1116.
260. Pisansky TM, Pugh SL, Greenberg RE, et al. Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer: the Radiation Therapy Oncology Group [0831] randomized clinical trial. *JAMA* 2014;311:1300–1307.
261. Zelefsky MJ, Shasha D, Branco RD, et al. Prophylactic sildenafil citrate improves selected aspects of sexual function in men treated by radiotherapy for prostate cancer. *J Urol* 2014;192:868–874.
262. Galalae RM, Martinez A, Mate T, et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. *Int J Radiat Oncol Biol Phys* 2004;58:1048–1055.
263. Demanes DJ, Rodriguez RR, Schour L, et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. *Int J Radiat Oncol Biol Phys* 2005;61:1306–1316.
264. Deger S, Boehmer D, Roigas J, et al. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer. *Eur Urol* 2005;47:441–448.
265. Yamada Y, Bhatia S, Zaider M, et al. Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer. *Brachytherapy* 2006;5:157–164.
266. Phan TP, Syed AM, Puthawala A, et al. High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. *J Urol* 2007;177:123–127.
267. Hoskin PJ, Rojas AM, Bownes PJ, et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. *Radiother Oncol* 2012;103:217–222.
268. D'Amico AV. Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. *Urology* 2002;60:32–37.
269. Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. *N Engl J Med* 2011;365:107–118.
270. Lee AK. Radiation therapy combined with hormone therapy for prostate cancer. *Semin Radiat Oncol* 2006;16:20–28.
271. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomized study. *Lancet Oncol* 2010;11:1066–1073.
272. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cyoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. *J Clin Oncol* 2003;21:3972–3978.
273. Roach M 3rd, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. *J Clin Oncol* 2003;21:1904–1911.
274. D'Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. *JAMA* 2004;292:821–827.
275. Crook J, Ludgate C, Malone S, et al. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. *Int J Radiat Oncol Biol Phys* 2004;60:15–23.
276. Bolla M, van Tienhoven G, de Reijke TM, et al. Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT—Results of the randomized EORTC Phase III trial 22961. *J Clin Oncol* 2007;25:5014.
277. Sasse AD, Sasse E, Carvalho AM, et al. Androgenic suppression combined with radiotherapy for the treatment of prostate adenocarcinoma: a systematic review. *BMC Cancer* 2012;12:54.
278. Zumsteg ZS, Spratt DE, Pei I, et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. *Eur Urol* 2013;64:895–902.
279. Merrick GS, Butler WM, Wallner KE, et al. Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam. *Int J Radiat Oncol Biol Phys* 2007;68:34–40.
280. Zumsteg ZS, Zelefsky MJ. Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care? *Lancet Oncol* 2012;13:e259–e269.
281. Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. *JAMA* 2011;306:2359–2366.
282. Nguyen PL, Chen MH, Beckman JA, et al. Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. *Int J Radiat Oncol Biol Phys* 2012;82:1411–1416.
283. Nanda A, Chen MH, Braccioforte MH, et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. *JAMA* 2009;302:866–873.
284. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. *J Urol* 2009;181:956–962.
285. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). *Lancet* 2005;366:572–578.
286. Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). *Lancet* 2012;380:2018–2027.

287. Wiegel T, Bartkowiak D, Bottke D, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. *Eur Urol* 2014 [Epub ahead of print]. doi: 10.1016/j.eururo.2014.03.011
288. Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. *J Clin Oncol* 2007;25:2035–2041.
289. Katz MS, Zelefsky MJ, Venkatraman ES, et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. *J Clin Oncol* 2003;21:483–489.
290. Pfister D, Bolla M, Briganti A, et al. Early salvage radiotherapy following radical prostatectomy. *Eur Urol* 2014;65:1034–1043.
291. Goenka A, Magsanoc JM, Pei X, et al. Long-term outcomes after high-dose postprostatectomy salvage radiation treatment. *Int J Radiat Oncol Biol Phys* 2012;84:112–118.
292. Briganti A, Karnes RJ, Joniau S, et al. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. *Eur Urol* 2013 [Epub ahead of print]. doi: 10.1016/j.eururo.2013.11.045.
293. Choo R, Hruby G, Hong J, et al. (IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy. *Int J Radiat Oncol Biol Phys* 2002;53:269–276.
294. Macdonald OK, Schild SE, Vora SA, et al. Salvage radiotherapy for palpable, locally recurrent prostate cancer after radical prostatectomy. *Int J Radiat Oncol Biol Phys* 2004;58:1530–1535.
295. Valicenti RK, Thompson J Jr, Albersen P, et al. Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. *Int J Radiat Oncol Biol Phys* 2013;86:822–828.
296. Eastham JA, Kattan MW, Rogers E, et al. Risk factors for urinary incontinence after radical prostatectomy. *J Urol* 1996;156:1707–1713.
297. Burri RJ, Stone NN, Unger P, et al. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. *Int J Radiat Oncol Biol Phys* 2010;77:1338–1344.
298. Vargas C, Swartz D, Vashi A, et al. Salvage brachytherapy for recurrent prostate cancer. *Brachytherapy* 2014;13:53–58.
299. Lahmer G, Lotter M, Kreppner S, et al. Protocol-based image-guided salvage brachytherapy. Early results in patients with local failure of prostate cancer after radiation therapy. *Strahlenther Onkol* 2013;189:668–674.
300. Chen CP, Weinberg V, Shinohara K, et al. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. *Int J Radiat Oncol Biol Phys* 2013;86:324–329.
301. Yamada Y, Kollmeier MA, Pei X, et al. A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy. *Brachytherapy* 2014;13:111–116.
302. Bahn DK, Lee F, Silverman P, et al. Salvage cryosurgery for recurrent prostate cancer after radiation therapy: a seven-year follow-up. *Clin Prostate Cancer* 2003;2:111–114.
303. Chin JL, Pautler SE, Mouraviev V, et al. Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications. *J Urol* 2001;165:1937–1941.
304. Donnelly BJ, Saliken JC, Ernst DS, et al. Role of transrectal ultrasound guided salvage cryosurgery for recurrent prostate carcinoma after radiotherapy. *Prostate Cancer Prostatic Dis* 2005;8:235–242.
305. Finley DS, Pouliot F, Miller DC, et al. Primary and salvage cryotherapy for prostate cancer. *Urol Clin North Am* 2010;37:67–82.
306. Ng CK, Moussa M, Downey DB, et al. Salvage cryoablation of the prostate: followup and analysis of predictive factors for outcome. *J Urol* 2007;178:1253–1257.
307. Pisters LL, Leibovici D, Blute M, et al. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. *J Urol* 2009;182:517–525.
308. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. *Cancer Res* 1941;1:293–297.
309. Huggins C, Stevens RE Jr, Hodges CV. Studies on prostatic cancer. II. The effect of castration on advanced carcinoma of the prostate gland. *Arch Surg* 1941;43:209–223.
310. Schally AV, Redding TW, Comaru-Schally AM. Inhibition of prostate tumors by agonistic and antagonistic analogs of LH-RH. *Prostate* 1983;4:545–552.
311. Tolis G, Ackman D, Stellos A, et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. *Proc Natl Acad Sci U S A* 1982;79:1658–1662.
312. Huggins C, Scott WW. Bilateral adrenalectomy in prostatic cancer. *Ann Surg* 1945;122:1031–1041.
313. Sanford EJ, Drago JR, Rohner TJ Jr, et al. Aminoglutethimide medical adrenalectomy for advanced prostatic carcinoma. *J Urol* 1976;115:170–174.
314. Trachtenberg J, Halpern N, Pont A. Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. *J Urol* 1983;130:152–153.
315. Neri RO. Antiandrogens. *Adv Sex Horm Res* 1976;2:233–262.
316. Peets EA, Henson MF, Neri R. On the mechanism of the anti-androgenic action of flutamide (alpha-alpha-alpha-trifluoro-2-methyl-4'-nitro-m-propionoluidide) in the rat. *Endocrinology* 1974;94:532–540.
317. Labrie F, Dupont A, Giguere M, et al. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer. *J Steroid Biochem* 1986;25:877–883.
318. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group. *Lancet* 1995;346:265–269.
319. Caubet JF, Tosteson TD, Dong EW, et al. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. *Urology* 1997;49:71–78.
320. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. *J Clin Oncol* 1996;14:1756–1764.
321. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. *N Engl J Med* 2004;351:1513–1520.
322. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *N Engl J Med* 2004;351:1502–1512.
323. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N Engl J Med* 2010;363:411–422.
324. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. *N Engl J Med* 2013;368:138–148.
325. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. *Lancet* 2010;376:1147–1154.
326. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. *N Engl J Med* 2013;369:213–223.
327. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. *N Engl J Med* 2011;364:1995–2005.
328. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med* 2012;367:1187–1197.
329. Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. *J Clin Oncol* 2012;30:1534–1540.
330. Tannock IF, Fizazi K, Ivanov S, et al. Afibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE). *J Clin Oncol* 2013;31:Abstr 13.
331. Quinn DI, Tangen CM, Hussain M, et al. SWOG S0421: Phase III study of docetaxel (D) and abiraterone (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC). *J Clin Oncol* 2012;30:Abstr 4511.
332. Fizazi K, Higano CS, Nelson JB, et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. *J Clin Oncol* 2013;31:1740–1747.
333. Araujo JC, Trudel GC, Saad F, et al. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial. *J Clin Oncol* 2013;31:Abstr LBA8.
334. Small E, Demkow T, Gerritsen WR, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). 2009;Abstr 7.
335. Petrylak DP, Fizazi K, Sternberg CN, et al. A phase III study to evaluate the efficacy and safety of docetaxel and prednisone (DP) with or without lenalidomide (LEN) in patients with castrate-resistant prostate cancer (CRPC): the MAINSAIL trial. *Ann Oncol* 2012;23:Abstr LBA24.
336. Scher HI, Jia X, Chi K, et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. *J Clin Oncol* 2011;29:2191–2198.
337. Oncogenex Pharmaceutical, Inc. OncoGenex announces top-line survival results of phase 3 SYNERGY trial evaluating custirsen for metastatic castrate-resistant prostate cancer. Accessed June 25, 2014. <http://ir.oncogenex.com/releasedetail.cfm?ReleaseID=842949>.
338. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. *Lancet* 2011;377:813–822.
339. Scher HI, Morris MJ, Basch E, et al. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. *J Clin Oncol* 2011;29:3695–3704.
340. Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. *Lancet Oncol* 2009;10:981–991.
341. Bennett CL, Tosteson TD, Schmitt B, et al. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. *Prostate Cancer Prostatic Dis* 1999;2:4–8.
342. The Leuprolide Study Group, Garnick MB, Glode LM. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. *N Engl J Med* 1984;311:1281–1286.
343. Cassileth BR, Soloway MS, Vogelzang NJ, et al. Patients' choice of treatment in stage D prostate cancer. *Urology* 1989;33:57–62.

344. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. *BJU Int* 2008;102:1531–1538.
345. Labrie F, Dupont A, Belanger A, et al. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. *J Urol* 1987;138:804–806.
346. Schulze H, Senge T. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate. *J Urol* 1990;144:934–941.
347. Schellhammer PF, Sharifi R, Block NL, et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. *Urology* 1997;50:330–336.
348. Bertagna C, De Cery A, Hucher M, et al. Efficacy of the combination of nilutamide plus orchiectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). *Br J Urol* 1994;73:396–402.
349. Schellhammer PF. An evaluation of bicalutamide in the treatment of prostate cancer. *Expert Opin Pharmacother* 2002;3:1313–1328.
350. Ahmadi H, Daneshmand S. Androgen deprivation therapy: evidence-based management of side effects. *BJU Int* 2013;111:543–548.
351. Flaig TW, Glode LM. Management of the side effects of androgen deprivation therapy in men with prostate cancer. *Expert Opin Pharmacother* 2008;9:2829–2841.
352. Holzbeierlein JM, Castle EP, Thrasher JB. Complications of androgen-deprivation therapy for prostate cancer. *Clin Prostate Cancer* 2003;2:147–152.
353. Gerber GS, Zagaja GP, Ray PS, et al. Transdermal estrogen in the treatment of hot flashes in men with prostate cancer. *Urology* 2000;55:97–101.
354. Morrow PK, Mattair DN, Hortobagyi GN. Hot flashes: a review of pathophysiology and treatment modalities. *Oncologist* 2011;16:1658–1664.
355. Strum SB, McDermed JE, Scholz MC, et al. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. *Br J Urol* 1997;79:933–941.
356. Diamond TH, Higano CS, Smith MR, et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. *Cancer* 2004;100:892–899.
357. Basaria S, Muller DC, Carducci MA, et al. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. *Cancer* 2006;106:581–588.
358. Basaria S, Lieb J 2nd, Tang AM, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. *Clin Endocrinol (Oxf)* 2002;56:779–786.
359. Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. *N Engl J Med* 2005;352:154–164.
360. Smith MR. Treatment-related osteoporosis in men with prostate cancer. *Clin Cancer Res* 2006;12:6315s–6319s.
361. Saad F, Higano CS, Sartor O, et al. The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. *Clin Genitourin Cancer* 2006;4:257–262.
362. Hanley DA, Adachi JD, Bell A, et al. Denosumab: mechanism of action and clinical outcomes. *Int J Clin Pract* 2012;66:1139–1146.
363. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. *N Engl J Med* 2009;361:745–755.
364. Smith MR, Morton RA, Barnette KG, et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. *J Urol* 2013;189:S45–S50.
365. Pirl WF, Siegel GI, Goode MJ, et al. Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. *Psychooncology* 2002;11:518–523.
366. Nelson CJ, Lee JS, Gamboa MC, et al. Cognitive effects of hormone therapy in men with prostate cancer: a review. *Cancer* 2008;113:1097–1106.
367. Salminen EK, Portin RI, Koskinen A, et al. Associations between serum testosterone fall and cognitive function in prostate cancer patients. *Clin Cancer Res* 2004;10:7575–7582.
368. Conteduca V, Di Lorenzo G, Tartarone A, et al. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy. *Crit Rev Oncol Hematol* 2013;86:42–51.
369. Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. *CA Cancer J Clin* 2010;60:194–201.
370. Bennett CL, Raisch DW, Sartor O. Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect. *Ann Intern Med* 2002;137:625.
371. Gleave ME, Goldenberg SL, Chin JL, et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. *J Urol* 2001;166:500–506.
372. Glass TR, Tangen CM, Crawford ED, et al. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. *J Urol* 2003;169:164–169.
373. Sylvester RJ, Denis L, de Voogt H. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group. *Eur Urol* 1998;33:134–143.
374. Noguchi M, Kikuchi H, Ishibashi M, et al. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. *Br J Cancer* 2003;88:195–201.
375. Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. *Cancer* 1988;61:195–202.
376. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. *N Engl J Med* 1998;339:1036–1042.
377. Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). *J Clin Oncol* 2006;24:3984–3990.
378. Choueiri TK, Xie W, D'Amico AV, et al. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. *Cancer* 2009;115:981–987.
379. Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. *Ann Intern Med* 2000;132:566–577.
380. Robinson MR, Smith PH, Richards B, et al. The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchiectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. *Eur Urol* 1995;28:273–283.
381. Geller J, Albert JD, Nachtsheim DA, et al. Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. *J Urol* 1984;132:693–696.
382. Titus MA, Schell MJ, Lih FB, et al. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. *Clin Cancer Res* 2005;11:4653–4657.
383. Mostaghel EA, Page ST, Lin DW, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. *Cancer Res* 2007;67:5033–5041.
384. Ryan CJ, Smith A, Lal P, et al. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression. *Urology* 2006;68:834–839.
385. Labrie F, Dupont A, Belanger A. Complete androgen blockade for the treatment of prostate cancer. *Important Adv Oncol* 1985;193–217.
386. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5710 patients. *Lancet* 1995;346:265–269.
387. Schmitt B, Bennett C, Seidenfeld J, et al. Maximal androgen blockade for advanced prostate cancer. *Cochrane Database Syst Rev* 2000:CD001526.
388. Blackard CE. The Veterans' Administration Cooperative Urological Research Group studies of carcinoma of the prostate: a review. *Cancer Chemother Rep* 1975;59:225–227.
389. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. *NCI Monogr* 1988:165–170.
390. Walsh PC. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. *Br J Urol* 1997;79:235–246.
391. Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. *J Clin Oncol* 2006;24:1868–1876.
392. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. *JAMA* 1999;281:1591–1597.
393. Antonarakis ES, Feng Z, Trock BJ, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. *BJU Int* 2012;109:32–39.
394. Zhou P, Chen MH, McLeod D, et al. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. *J Clin Oncol* 2005;23:6992–6998.
395. Iversen P, Tveter K, Varenhorst E. Randomised study of Casodex 50 MG monotherapy vs orchiectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group. *Scand J Urol Nephrol* 1996;30:93–98.
396. Iversen P, Tyrell CJ, Kaisary AV, et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. *Urology* 1998;51:389–396.
397. Scher HI, Liebertz C, Kelly WK, et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. *J Clin Oncol* 1997;15:2928–2938.
398. Klotz LH, Herr HW, Morse MJ, et al. Intermittent endocrine therapy for advanced prostate cancer. *Cancer* 1986;58:2546–2550.

399. Bruchovsky N, Rennie PS, Coldman AJ, et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. *Cancer Res* 1990;50:2275–2282.
400. Sato N, Gleave ME, Bruchovsky N, et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. *J Steroid Biochem Mol Biol* 1996;58:139–146.
401. Crook JM, O'Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. *N Engl J Med* 2012;367:895–903.
402. Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. *N Engl J Med* 2013;368:1314–1325.
403. Tsai HT, Penson DF, Makambi KH, et al. Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis. *Urology* 2013;82:327–333.
404. Niraula S, Le LW, Tannock IF. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. *J Clin Oncol* 2013;31:2029–2036.
405. Botrel TE, Clark O, dos Reis RB, et al. Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis. *BMC Urol* 2014;14:9.
406. Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. *Lancet* 2012;379:39–46.
407. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. *J Urol* 2003;169:2008–2012.
408. Smith MR, Saad F, Oudard S, et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. *J Clin Oncol* 2013;31:3800–3806.
409. Beltran H, Tomlins S, Aparicio A, et al. Aggressive variants of castration-resistant prostate cancer. *Clin Cancer Res* 2014;20:2846–2850.
410. Epstein JI, Amin MB, Beltran H, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. *Am J Surg Pathol* 2014;38:756–767.
411. Pond GR, Sonpavde G, de Wit R, et al. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. *Eur Urol* 2014;65:3–6.
412. Aparicio AM, Harzstark AL, Corn PG, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. *Clin Cancer Res* 2013;19:3621–3630.
413. Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. *J Clin Oncol* 1993;11:2167–2172.
414. Crawford ED, Sartor O, Chu F, et al. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. *J Urol* 2006;175:533–536.
415. Kelly WK, Slovin S, Scher HI. Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. *Urol Clin North Am* 1997;24:421–431.
416. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. *J Clin Oncol* 1993;11:1566–1572.
417. Oh WK, Manola J, Bittmann L, et al. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. *Urology* 2003;62:99–104.
418. Crombie C, Raghavan D, Page J, et al. Phase II study of megestrol acetate for metastatic carcinoma of the prostate. *Br J Urol* 1987;59:443–446.
419. Courtney KD, Taplin ME. The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer. *Curr Opin Oncol* 2012;24:272–277.
420. Smith DC, Redman BG, Flaherty LE, et al. A phase II trial of oral diethylstilbestrol as a second-line hormonal agent in advanced prostate cancer. *Urology* 1998;52:257–260.
421. Pomerantz M, Manola J, Taplin ME, et al. Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. *J Urol* 2007;177:2146–2150.
422. Aggarwal R, Weinberg V, Small EJ, et al. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels. *Clin Genitourin Cancer* 2009;7:E71–E76.
423. Kitahara S, Umeda H, Yano M, et al. Effects of intravenous administration of high dose-diethylstilbestrol diphosphate on serum hormonal levels in patients with hormone-refractory prostate cancer. *Endocr J* 1999;46:659–664.
424. Estramustine phosphate in prostate cancer. Seminar. *Urology* 1984;23:1–88.
425. Bland LB, Garzotto M, DeLoughery TC, et al. Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. *Cancer* 2005;103:717–723.
426. Kandola S, Anyamene N, Payne H, et al. Transdermal oestrogen therapy as a second-line hormonal intervention in prostate cancer: a bad experience. *BJU Int* 2007;99:53–55.
427. Small EJ, Baron AD, Fippin L, et al. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. *J Urol* 1997;157:1204–1207.
428. Ryan CJ, Halabi S, Ou SS, et al. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus androgen withdrawal: results from a cancer and leukemia group B study. *Clin Cancer Res* 2007;13:2030–2037.
429. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). *J Clin Oncol* 2004;22:1025–1033.
430. Tannock I, Gospodarowicz M, Meakin W, et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. *J Clin Oncol* 1989;7:590–597.
431. Montgomery B, Cheng HH, Drechsler J, et al. Glucocorticoids and prostate cancer treatment: friend or foe? *Asian J Androl* 2014;16:354–358.
432. Ryan CJ, Molina A, Li J, et al. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. *J Clin Oncol* 2013;31:2791–2798.
433. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. *J Clin Oncol* 1999;18:2506–2513.
434. Bouchet BP, Galmarini CM. Cabazitaxel, a new taxane with favorable properties. *Drugs Today (Bare)* 2010;46:735–742.
435. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. *J Clin Oncol* 2005;23:8253–8261.
436. Tamae D, Byrns M, Marek B, et al. Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum. *J Steroid Biochem Mol Biol* 2013;138:281–289.
437. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. *Cancer Res* 2008;68:4447–4454.
438. Barrie SE, Potter GA, Goddard PM, et al. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). *J Steroid Biochem Mol Biol* 1994;50:267–273.
439. O'Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. *Br J Cancer* 2004;90:2317–2325.
440. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. *J Clin Oncol* 2008;26:4563–4571.
441. Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. *J Clin Oncol* 2010;28:1481–1488.
442. Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. *J Clin Oncol* 2010;28:1489–1495.
443. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. *J Clin Oncol* 2010;28:1496–1501.
444. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. *Lancet Oncol* 2012;13:983–992.
445. Rathkopf DE, Smith MR, de Bono JS, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). *Eur Urol* 2014 [Epub ahead of print]. doi: 10.1016/j.eururo.2014.02.056.
446. Scher HI, Beer TM, Higano CS, et al. Antitumor activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. *Lancet* 2010;375:1437–1446.
447. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med* 2014;371:424–433.
448. Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. *Cancer Res* 2012;72:1494–1503.
449. Rathkopf DE, Morris MJ, Fox JJ, et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. *J Clin Oncol* 2013;31:3525–3530.
450. Stein MN, Patel N, Bershadskiy A, et al. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. *Asian J Androl* 2014;16:387–400.
451. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. *J Clin Oncol* 2000;18:3894–3903.
452. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. *J Clin Oncol* 2006;24:3089–3094.
453. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. *J Clin Oncol* 2010;28:1099–1105.
454. DiPaola RS, Plante M, Kaufman H, et al. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. *J Transl Med* 2006;4:1.
455. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 2010;363:711–723.

456. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *N Engl J Med* 2011;364:2517–2526.
457. Slovin SF, Higano CS, Hamid O, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. *Ann Oncol* 2013;24:1813–1821.
458. Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. *Lancet Oncol* 2014;15:700–712.
459. Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. *J Clin Oncol* 2013;31:412–419.
460. Dalrymple SL, Becker RE, Isaacs JT. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. *Prostate* 2007;67:790–797.
461. Gupta N, Ustvani OA, Shen L, et al. Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer. *Onco Targets Ther* 2014;7:223–234.
462. Isaacs JT, Pili R, Qian DZ, et al. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. *Prostate* 2006;66:1768–1778.
463. Pili R, Haggman M, Stadler WM, et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. *J Clin Oncol* 2011;29:4022–4028.
464. Armstrong AJ, Haggman M, Stadler WM, et al. Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. *Clin Cancer Res* 2013;19:6891–6901.
465. Smith MR, Saad F, Egerdie B, et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. *J Urol* 2009;182:2670–2675.
466. McDermott RS, Anderson PR, Greenberg RE, et al. Cranial nerve deficits in patients with metastatic prostate carcinoma: clinical features and treatment outcomes. *Cancer* 2004;101:1639–1643.
467. Loblaw A, Mitera G. Malignant extradural spinal cord compression in men with prostate cancer. *Curr Opin Support Palliat Care* 2011;5:206–210.
468. Venkitaraman R, Sohaib SA, Barbachano Y, et al. Detection of occult spinal cord compression with magnetic resonance imaging of the spine. *Clin Oncol (R Coll Radiol)* 2007;19:528–531.
469. Falkmer U, Jarhult J, Wersall P, et al. A systematic overview of radiation therapy effects in skeletal metastases. *Acta Oncol* 2003;42:620–633.
470. Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases. *J Natl Cancer Inst* 2005;97:798–804.
471. Kaasa S, Brenne E, Lund JA, et al. Prospective randomised multicenter trial on single fraction radiotherapy (8 Gy x 1) versus multiple fractions (3 Gy x 10) in the treatment of painful bone metastases. *Radiother Oncol* 2006;79:278–284.
472. Anderson P, Nunez R. Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma. *Expert Rev Anticancer Ther* 2007;7:1517–1527.
473. Gartrell BA, Saad F. Managing bone metastases and reducing skeletal related events in prostate cancer. *Nat Rev Clin Oncol* 2014;11:335–345.
474. Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. *Int J Radiat Oncol Biol Phys* 1993;25:805–813.
475. Farhanghi M, Holmes RA, Volkert WA, et al. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. *J Nucl Med* 1992;33:1451–1458.
476. Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. *J Nucl Med* 1993;34:1839–1844.
477. Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. *Urology* 2004;63:940–945.
478. Autio KA, Pandit-Taskar N, Carrasquillo JA, et al. Repetitively dosed docetaxel and (1)(5)(3)samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer. *Cancer* 2013;119:3186–3194.
479. Nilsson S, Larsen RH, Fossa SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. *Clin Cancer Res* 2005;11:4451–4459.
480. Dreicer R, Jones R, Oudard S, et al. Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial). *J Clin Oncol* 2014;32:Abstr 7.
481. OncoGenex Pharmaceuticals, Inc. OncoGenex Announces Top-Line Survival Results of Phase 3 SYNERGY Trial Evaluating Custirsen for Metastatic Castrate-Resistant Prostate Cancer [press release]. April 28, 2014. Accessed June 20, 2014. <http://ir.oncogenex.com/releasedetail.cfm?ReleaseID=842949>.
482. Dreicer R, MacLean D, Suri A, et al. Phase I/II trial of orteronel (TAK-700)—an investigational 17,20-lyase inhibitor—in patients with metastatic castration-resistant prostate cancer. *Clin Cancer Res* 2014;20:1335–1344.
483. Petrylak D, Gandhi JG, Clark WR, et al. A phase I/II study of safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Updated phase II results. *J Clin Oncol* 2013;31:Abstr 59.
484. Saad F, Hotte S, North S, et al. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. *Clin Cancer Res* 2011;17:5765–5773.
485. Rathkopf D, Scher HI. Androgen receptor antagonists in castration-resistant prostate cancer. *Cancer J* 2013;19:43–49.
486. Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. *Cancer Cell* 2011;19:575–586.
487. Sprenger CC, Plymate SR. The link between androgen receptor splice variants and castration-resistant prostate cancer. *Horm Cancer* 2014;5:207–217.
488. Antonarakis ES, Lu C, Luber B, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. *N Engl J Med* 2014 [Epub ahead of print].
489. Balbas MD, Evans MJ, Hosfield DJ, et al. Overcoming mutation-based resistance to antiandrogens with rational drug design. *Elife* 2013;2:e00499.
490. Arora VK, Schenkein E, Murali R, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. *Cell* 2013;155:1309–1322.
491. Messing EM, Manola J, Sarosy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. *N Engl J Med* 1999;341:1781–1788.
492. Sweeney C, Chen YH, Carducci MA, et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. *J Clin Oncol* 2014;32:Abstr LBA2.
493. McKay RR, Choueiri TK, Taplin ME. Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer. *Drugs* 2013;73:1417–1430.
494. Taplin ME, Montgomery RB, Logothetis C, et al. Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study. *J Clin Oncol* 2012;30:Abstr 4521.